13F Holdings
中文EN

ICCC IMMUCELL CORP /DE/

In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 811641 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY19.6%
TTM net income YoY-19.1%
TTM EPS YoY-32.1%
Revenue 3-yr CAGR26.8%
Net income 3-yr CAGR—

Margins

Gross margin40.8%
Operating margin14.5%
Net margin5.7%
FCF margin16.3%
EBITDA margin21.0%

Returns

ROE6.0%
ROA4.2%
ROIC (approx.)13.8%
Asset turnover0.73x

Leverage & solvency

Liabilities / assets31.7%
Debt / equity0.24x
Current ratio4.61x
Interest coverage12.19x

Cash quality & payout

Operating cash flow / net income4.17x
Accruals ratio-13.2%
Payout ratio—
Capex / revenue7.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$27.64M$26.49M$17.47M$18.57M$19.24M
Cost of revenue$16.20M$18.55M$13.60M$10.92M$10.59M
Gross profit$11.45M$7.94M$3.87M$7.65M$8.66M
R&D expense$3.04M$3.90M$4.39M$4.49M$4.17M
SG&A expense$3.20M$2.22M$2.13M$2.26M$1.73M
Operating income$1.65M-$1.64M-$5.75M-$2.30M$257,385
Interest expense$493,384$568,725$475,598$348,536$314,359
Pretax income-$1.03M-$2.15M-$5.77M-$2.49M-$69,127
Income tax$11,570$10,056$4,627$7,672$9,165
Net income-$1.04M-$2.16M-$5.77M-$2.49M-$78,292
EBITDA$4.43M$1.09M-$3.05M$169,536$2.70M
EPS (basic)-0.12-0.26-0.75-0.32-0.01
EPS (diluted)-0.12-0.26-0.75-0.32-0.01
Weighted avg. shares (diluted)9.03M8.17M7.75M7.75M7.59M
Balance sheet
Cash & equivalents$3.81M$3.76M$978,741$5.79M$10.19M
Receivables$3.42M$3.77M$2.19M$1.76M$2.69M
Inventory$9.27M$7.11M$7.81M$6.04M$3.09M
Current assets$16.94M$15.04M$11.47M$13.99M$16.26M
PP&E, net$21.07M$25.35M$27.58M$28.44M$26.89M
Goodwill$95,557$95,557$95,557$95,557$95,557
Intangibles$0$19,104$38,208$57,312$76,416
Total assets$42.53M$45.10M$43.81M$44.86M$44.47M
Current liabilities$3.98M$4.41M$4.20M$3.07M$2.53M
Short-term debt$1.61M$1.50M$1.43M$8.90M—
Long-term debt$7.49M$9.04M$10.54M$9.19M$812,207
Total debt$9.10M$10.54M$11.97M$18.09M$812,207
Total liabilities$15.48M$17.58M$18.82M$14.48M$11.89M
Shareholders' equity$27.06M$27.52M$24.99M$30.38M$32.58M
Net debt$5.29M$6.78M$10.99M$12.30M-$9.37M
Shares outstanding9.05M8.98M7.75M7.75M7.74M
Cash flow statement
Operating cash flow$2.48M$357,903-$4.67M-$1.54M$954,170
Capital expenditure$1.25M$465,725$1.89M$3.98M$2.61M
Free cash flow$1.22M-$107,822-$6.57M-$5.52M-$1.65M
Investing cash flow-$1.21M-$461,225-$1.89M-$3.96M-$1.60M
Financing cash flow-$1.21M$2.88M$1.75M$1.11M$3.88M
Depreciation & amortization$2.78M$2.73M$2.70M$2.47M$2.44M
Stock-based compensation$295,871$325,551$368,866$266,244$144,313

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.